Plowing ahead…

Schering, Merck Cholesterol Prescriptions Slide

schering-200.gifNEW YORK (Reuters) – U.S. prescriptions of Schering-Plow Corp’s cholesterol drugs fell 13 percent in February from a month earlier, following results of a controversial study, the drug maker said on Tuesday.

The drugs, Zetia and Vytorin, fell to 2.77 million total prescriptions in February from 3.19 million in January, Schering-Plow said in a filing. Schering-Plow sells the drugs with Merck & Co in a joint venture.

“Although the prescription data have shown some early signs of stabilization, there are limitations to this prescription data and it is too early to discern any trends,” Schering-Plow said.

It’s amazing that your news agency releases this story with the name Schering-Plough MISSPELLED throughout the article as Schering-Plow. THREE journalists let this error go undetected!  

John Y.

This was not human error – not even sloppy use of a spell-check. The spelling was correct for most of our services, but a renegade program changing British spellings to American spellings kicked in on one news feed. And yes, it was a bit ironic that it happened the week Arthur C. Clarke died: GBU Editor

No comments so far

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see